GLS 5300

Drug Profile

GLS 5300

Alternative Names: GLS-5300; MERS DNA vaccine - Inovio Pharmaceuticals

Latest Information Update: 02 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer GeneOne Life Science; Inovio Pharmaceuticals; Walter Reed Army Institute of Research
  • Class Antivirals; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Middle East respiratory syndrome coronavirus

Most Recent Events

  • 23 Feb 2017 Interim immunogenicity and safety results from the phase I trial were released by Inovio Pharmaceuticals
  • 08 Aug 2016 GeneOne completes enrolment in its phase I trial for Middle East respiratory syndrome coronavirus (Prevention) in USA
  • 28 Jan 2016 Phase-I clinical trials in Middle East respiratory syndrome coronavirus (Prevention) in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top